Infex to present RESP-X Phase I data at ERS Congress September 2, 2024 RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with chronic Pseudomonas aeruginosa (Pa) colonisation. ...
A growing body of evidence demonstrates that isolated SPMs show efficacy at very low doses and have been successively used as therapeutic drugs to treat pain and infection in experimental models showing no side effects. Moreover, SPMs work as immunoresolvents and some of them present long-lasting...
Viruses with complex life cycles, such asHIV, can be more difficult to treat. First, HIV targets CD4-positive white blood cells, which are necessary for a normal immune response to infection. Second, HIV is aretrovirus, meaning that it converts its RNA genome into a DNA copy that integrate...
Pseudomonas aeruginosa infections are difficult to treat due to rapid development of antibiotic drug resistance. The synergistic combination of already-in-use drugs is an alternative to developing new antibiotics to combat antibiotic-resistant bacteria. Here we demonstrate that bismuth-based drugs (bismuth...
The authors therefore developed a more sensitive assay to evaluate antimicrobial activity. They created a strain of Pseudomonas aeruginosa containing a luciferase reporter gene incorporated into a constitutively active gene involved in ATP- dependent flagellar biosynthesis. So long as the bacterium produces...
Do not use for eye infections caused by non-susceptible organisms, especially Pseudomonas spp. or if hypersensitivity to fusidic acid or any of the other ingredients is known. Discontinue use if hypersensitivity to the product develops. Cautions: Do not use the same tube to treat different dogs....
Over the past few decades research related to the ligand targeted therapy (LTT) increased tremendously aiming to treat various pathologies, mainly cancers with well exclusive markers. Malignant tumors are known to induce elevated levels of a variety of proteins and peptides known as cancer “markers...
On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of antibiotics, especially carbapenem resistance, in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa has ri...
N. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Curr Pharm Des 21, 4106-4111 (2015).Younis W, Thangamani S, Seleem MN. Repurposing Non-antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Current pharmaceutical design. 2015....
Use of co-trimoxazole; Susceptibility of methicillin resistant S aureus to co-trimoxazole; Reintroduction of chloramphenicol as a drug to treated severe infections caused by vancomycin resistant enterococci; Use of colistin to treated infections caused by a strain of Pseudomonas aeruginosa; Pace of ...